Mangana Joanna, Zipser Marie C, Conrad Curdin, Oberholzer Patrick A, Cozzio Antonio, Knuth Alexander, French Lars E, Dummer Reinhard
Department of Dermatology,University Hospital of Zurich, Gloriastrasse 31, Zurich, Switzerland.
Eur J Dermatol. 2008 Sep-Oct;18(5):566-70. doi: 10.1684/ejd.2008.0490. Epub 2008 Aug 8.
Liposomal pegylated doxorubicin is an encapsulation form of doxorubicin, with an improved pharmacokinetic profile and the ability to selectively accumulate into tumor tissue. As a result, the tolerated dose of the drug can be increased, followed by a reduced incidence of neutropenia and cardiotoxicity in comparison to doxorubucin treatment. However, a common adverse dose-schedule limiting effect of the treatment is palmoplantar erythrodysesthesia syndrome. In this retrospective study we included six patients hospitalised in the University Hospital of Zurich during the last 2 years, in connection with side effects caused by pegylated liposomal doxorubicin. These patients received this chemotherapeutic agent for treatment of various malignancies such as breast cancer, ovarian cancer, mycosis fungoides and cutaneous B-cell lymphoma. Three of six patients in this study developed classical palmoplantar erythrodysesthesia, one developed palmoplantar erythrodysesthesia associated with extensive bullous disease, one developed eruption of lymphocyte recovery syndrome and one developed intertrigo like dermatitis with stomatitis. Pegylated liposomal doxorubicin induces various skin reactions including palmoplantar erythrodysesthesia syndrome. However, the exact clinical presentation might depend on pre-existing skin diseases.
脂质体聚乙二醇化阿霉素是阿霉素的一种包封形式，具有改善的药代动力学特征以及选择性积聚于肿瘤组织的能力。因此，与阿霉素治疗相比，该药物的耐受剂量可以提高，随后中性粒细胞减少和心脏毒性的发生率降低。然而，该治疗常见的不良剂量 - 方案限制效应是手足红斑感觉异常综合征。在这项回顾性研究中，我们纳入了过去两年在苏黎世大学医院住院的6例患者，这些患者与聚乙二醇化脂质体阿霉素引起的副作用有关。这些患者接受这种化疗药物治疗各种恶性肿瘤，如乳腺癌、卵巢癌、蕈样肉芽肿和皮肤B细胞淋巴瘤。本研究中的6例患者中有3例出现典型的手足红斑感觉异常，1例出现与广泛大疱性疾病相关的手足红斑感觉异常，1例出现淋巴细胞恢复综合征皮疹，1例出现间擦疹样皮炎伴口腔炎。聚乙二醇化脂质体阿霉素可诱发包括手足红斑感觉异常综合征在内的各种皮肤反应。然而，确切的临床表现可能取决于既往存在的皮肤疾病。
